Chimera Peptides
Chimera Peptides' purity-focus record is narrow but mostly strong, led by Retatrutide with repeated identity matches, 99.6–99.9% purity, and fills in range. Tirzepatide is more mixed because of one purity miss and earlier overfill; recent results are clean, but batch IDs are often absent.
Corporate filings, a clientHold legacy domain, and a shared live-chat key complicate Chimera’s public identity. The report also maps the US-order alert, April fulfillment complaints, restrictive payment terms, and a deleted X post.
Unlock original COAs
View and download original lab PDFs for Finnrick tests, including Chimera Peptides rows.
Cancel anytime
| Date | Result | Test | Lab | Purity | Dosage | Label | COA |
|---|---|---|---|---|---|---|---|
| 5 Aug 2026 | Pass | Retatrutide Chimera Peptides | lab name | View COA | |||
| 5 Aug 2026 | Pass | Retatrutide Chimera Peptides | lab name | View COA | |||
| 5 Aug 2026 | Pass | Retatrutide Chimera Peptides | lab name | View COA | |||
| 1 Jul 2026 | Pass | Tirzepatide Chimera Peptides | lab name | View COA | |||
| 25 May 2026 | Pass | Retatrutide Chimera Peptides | lab name | View COA | |||
| 19 May 2026 | Pass | Tirzepatide Chimera Peptides | lab name | View COA | |||
| 28 Apr 2026 | Pass | Retatrutide Chimera Peptides | lab name | View COA | |||
| 27 Apr 2026 | Pass | Retatrutide Chimera Peptides | lab name | View COA | |||
| 23 Apr 2026 | Pass | Tirzepatide Chimera Peptides | lab name | View COA | |||
| 2 Apr 2026 | Pass | Tirzepatide Chimera Peptides | lab name | View COA | |||
About Chimera Peptides test results from Finnrick
Chimera Peptides is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 2 peptides and 23 tests, including ratings, observed price signals, recent test dates, and correction history where available.
Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.
The most visible Chimera Peptides peptides in this dataset are Retatrutide (14 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.
Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 23 recent tests.